Ankur Drugs & Pharma (Delisted) financials and balance sheet

BSE: 531683

Last traded ₹3.65 on 10 Sep 2013

Delisted on 23 Aug 2017.

5 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Ankur Drugs & Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹1,067 Cr, year to Mar 2010A loss in 2 of the 5 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2012

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue153
  2. Operating expenses−181
  3. Operating profit−28
  4. Depreciation−66
  5. Other income+0.1
  6. One-off items−23
  7. Finance costs−73
  8. Profit before tax−190
  9. Tax−31
  10. Net profit−222

Profit and loss

Standalone, ₹ crore, years to March.Ankur Drugs & Pharma quarterly results

₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012
Revenue from operations6749641,067824153
568785855691181
Materials and goods bought––––19
Operating profit before depreciation106179212133−28
Operating margin15.7%18.5%19.9%16.1%−18.4%
Depreciation and amortisation522276166
Operating profit after depreciation10115718672−94
Other income12210
Finance costs24536910873
Profit before one-off items and tax–106119−36−167
One-off items––1−9−23
Profit before tax77106120−44−190
Tax1212342131
Net profit654786−65−222
Net margin9.6%4.9%8.1%−7.9%−144.7%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2008, Mar 2009, Mar 2010 and Mar 2011 they do not, so they are left blank.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2008Mar 2009Mar 2010Mar 2011Mar 2012
Earnings per share₹54.82₹25.13₹44.56−₹33.67−₹114.56
Diluted earnings per share₹37.47₹18.94₹30.33−₹26.15−₹39.94
Market cap at the year end (₹ crore)23012939110129

Ratios

Standalone, years to March.

RatioMar 2008Mar 2009Mar 2010Mar 2011Mar 2012
Revenue growth–43.1%10.7%−22.8%−81.4%
Operating profit growth–69.0%18.7%−37.5%–
Net profit growth–−27.7%84.2%––
Earnings per share growth–−54.2%77.3%––
Interest cover4.13.02.70.7–
Interest cover is left blank for the year to Mar 2012: operating profit after depreciation is a loss, and a loss covers no interest bill.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2012.

Measure5 years3 years
Revenue growth, yearly rate–−45.8%
Operating margin, average10.4%5.9%
Net margin, average−26.0%−48.2%
Interest cover, average2.61.7

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2008Mar 2009Mar 2010Mar 2011Mar 2012
Effective tax ratePublished threshold 17.16 per cent15.5211.0928.19––
A threshold marked as ours has no published figure; it is the line we read the check against.